喀麦隆HIV-1各亚型整合酶耐药突变与保守区域基线分析:资源有限地区多替拉韦转换的意义
该横断面研究纳入喀麦隆918例未使用整合酶链转移抑制剂(INSTI)的HIV-1感染者(89例未治疗,829例经治),评估整合酶耐药突变(DRMs)和保守区域。总体INSTI-DRMs流行率为0.8%(95%CI 0.4-1.7),未治疗者0.0%(0.0-4.0)与经治者0.9%(0.5-1.9)无显著差异(P=0.44)。辅助突变见于33.8%(95%CI 30.9-37.0),CRF02_AG亚型辅助突变频率显著高于非AG亚型(41.4% vs 27.1%,P<0.001)。
要点
- 喀麦隆INSTI初治人群基线INSTI-DRMs低于1%,支持多替拉韦方案有效性。
- 辅助突变总体33.8%,CRF02_AG亚型显著高于非AG亚型(41.4% vs 27.1%)。
- 整合酶288个氨基酸位点中58.3%高度保守,但辅助突变变异需监测。
核心结论
- 喀麦隆INSTI初治患者基线INSTI-DRMs低于1%,提示多替拉韦方案可能有效。
- 尽管各亚型间整合酶高度保守,主要流行株辅助突变变异需在扩大多替拉韦使用时监测INSTI-DRMs选择。
研究设计与样本
- 横断面研究纳入喀麦隆918例未使用INSTI的HIV-1感染者,包括89例未治疗和829例经治患者。
- 使用Stanford HIVdb v8.9-1和2019 IAS-USA列表解读INSTI-DRMs,变异率<1%的氨基酸位点定义为高度保守。
- 通过系统发育进行亚型分析。
主要发现
- 总体INSTI-DRMs流行率为0.8%(95%CI 0.4-1.7),未治疗者0.0%(0.0-4.0),经治者0.9%(0.5-1.9),P=0.44。
- 辅助突变总体33.8%(95%CI 30.9-37.0),未治疗者38.2%(28.1-49.1),经治者33.4%(30.4-36.7),P=0.21。
- 288个整合酶氨基酸位点中58.3%高度保守,主要区域包括V75-G82、E85-P90、H114-G118、K127-W132、E138-G149、Q168-L172、T174-V180、W235-A239和L241-D253。
- 发现37个进化支,包括M组(92.3%)、N组(1.4%)、O组(6.2%)和P组(0.1%);M组中CRF02_AG占47.4%。
- CRF02_AG亚型辅助突变频率41.4%(95%CI 36.8-46.0)显著高于非AG亚型27.1%(95%CI 23.3-31.2),P<0.001。
关键数值与推荐
- INSTI-DRMs总体流行率0.8%(95%CI 0.4-1.7),低于1%。
- 辅助突变总体33.8%(95%CI 30.9-37.0),CRF02_AG为41.4%(95%CI 36.8-46.0),非AG为27.1%(95%CI 23.3-31.2),P<0.001。
- 288个整合酶氨基酸位点中58.3%高度保守。
临床怎么用
- 在资源有限地区转换至多替拉韦方案前,应了解当地HIV-1整合酶变异和保守区域。
- 喀麦隆基线INSTI-DRMs低,支持多替拉韦方案使用,但需监测辅助突变选择。
- CRF02_AG亚型辅助突变频率较高,提示需关注该亚型人群的耐药监测。
局限性
- 横断面设计无法评估耐药突变随时间的选择趋势。
- 辅助突变对INSTI疗效的临床影响未在研究中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transition to dolutegravir-based regimens in resource-limited settings (RLS) requires prior understanding of HIV-1 integrase variants and conserved regions. Therefore, we evaluated integrase drug resistance mutations (DRMs) and conserved regions amongst integrase strand transfer inhibitor (INSTI)-naive patients harbouring diverse HIV-1 clades in Cameroon. METHODS: A cross-sectional study was conducted amongst 918 INSTI-naive patients from Cameroon (89 ART-naive and 829 ART-experienced patients). HIV-1 sequences were interpreted regarding INSTI-DRMs using the Stanford HIVdb v8.9-1 and the 2019 IAS-USA list. Amino acid positions with <1% variability were considered as highly conserved. Subtyping was performed by phylogeny. RESULTS: Overall prevalence (95% CI) of INSTI-DRMs was 0.8% (0.4-1.7), with 0.0% (0.0-4.0) amongst ART-naive versus 0.9% (0.5-1.9) amongst ART-experienced patients; P = 0.44. Accessory mutations (95% CI) were found in 33.8% (30.9-37.0), with 38.2% (28.1-49.1) amongst ART-naive versus 33.4% (30.4-36.7) amongst ART-experienced patients; P = 0.21. Of 288 HIV-1 integrase amino acid positions, 58.3% were highly conserved across subtypes in the following major regions: V75-G82, E85-P90, H114-G118, K127-W132, E138-G149, Q168-L172, T174-V180, W235-A239 and L241-D253. Wide genetic diversity was found (37 clades), including groups M (92.3%), N (1.4%), O (6.2%) and P (0.1%). Amongst group M, CRF02_AG was predominant (47.4%), with a significantly higher frequency (95% CI) of accessory mutations compared with non-AG [41.4% (36.8-46.0) versus 27.1% (23.3-31.2) respectively; P < 0.001]. CONCLUSIONS: The low baseline of INSTI-DRMs (<1%) in Cameroon suggests effectiveness of dolutegravir-based regimens. In spite of high conservation across clades, the variability of accessory mutations between major circulating strains underscores the need for monitoring the selection of INSTI-DRMs while scaling up dolutegravir-based regimens in RLS.
引用
- Semengue ENJ, Armenia D, Inzaule S, et al. Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. J Antimicrob Chemother. 2021. PMID: 33501504. doi:10.1093/jac/dkab004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。